If someone is looking for convincing arguments about the wildly publicized doom of the hedge fund business, they don’t need to look far beyond the 2017 list of the highest paid...
Keep Reading →
May 23 - Hedge Fund Analysis, Hedge Funds, News
The markets are relatively quiet today as there are no major economic releases. The Dow Jones index is down 10 points, while the S&P 500 is 0.23% in the red.
Keep Reading →
March 20 - News
Founded in 2001, JANA Partners is led by billionaire Barry Rosenstein, along with co-portfolio managers David DiDomenico and Scott Ostfeld.
Keep Reading →
March 9 - Hedge Fund Analysis, Hedge Funds, News
Insider trading can be either legal or illegal.
Keep Reading →
March 2 - Insider Trading, News
Julian Robertson is an iconic hedge fund manager who started Tiger Management in 1980.
Keep Reading →
February 27 - Hedge Funds, News
Bristol-Myers Squibb Co (NYSE:BMY) will sell senior notes that are unsecured worth $1.5 billion.
Keep Reading →
February 23 - News, Stock Analysis
Reports indicate that the market for immuno-oncology drugs could grow to $25 billion in the next ten years.
Keep Reading →
February 21 - News, Stock Analysis
2016 was again a dismal year for the hedge fund industry, with a lot of hedge funds failing to beat the benchmark and some trailing it by a huge margin.
Keep Reading →
February 15 - Hedge Fund Analysis, Hedge Funds, News
Merck & Co., Inc. (NYSE:MRK) has agreed to share a portion of Keytruda sales with Bristol-Myers Squibb Co (NYSE:BMY) and Ono Pharmaceutical Co., Ltd.
Keep Reading →
January 24 - News, Stock Analysis
Bristol-Myers Squibb Co (NYSE:BMY) has opted to extend the research term of its discovery collaboration agreement with Five Prime Therapeutics Inc (NASDAQ:FPRX).
Keep Reading →
January 5 - News, Stock Analysis
After a strong 2015, health care stocks are leading the way lower in 2016. And it’s been an even uglier year for biotechnology company Gilead Sciences, Inc.
Keep Reading →
December 23 - News, Stock Analysis
There is a need for additional funding towards the development and clinical studies of AndexXa, a new compound that is a prospective antidote for Factor Xa inhibitors.
Keep Reading →
December 20 - News, Stock Analysis
Billionaire investors are successful for a reason. They do not funnel their money in ordinary places.
Keep Reading →
December 5 - Hedge Fund Analysis, Hedge Funds, News
David E. Shaw is an American computer scientist and investor who founded D.E. Shaw & Co., L.P. in 1988. The hedge fund manages a 13F portfolio of over $59.68 billion. David E.
Keep Reading →
December 5 - Hedge Fund Analysis, Hedge Funds, News
Renaissance Technologies is probably the best quant hedge fund in the market.
Keep Reading →
December 2 - Hedge Funds, News
Like everyone else, elite investors make mistakes.
Keep Reading →
November 27 - Hedge Funds, News
Hedge fund legend Julian Robertson closed his hedge fund Tiger Management to outside investors way back in 2000 and has been using it as a vehicle to manage his own money since...
Keep Reading →
November 25 - Dividend Stocks, Hedge Fund Analysis, Hedge Funds, News
Tiger Management is a New York-based hedge fund founded in 1980 by legendary investor and billionaire Julian Robertson.
Keep Reading →
November 21 - ETF Trading, Hedge Fund Analysis, Hedge Funds, News
Opus Point Partners Management is a New York-based fund led by Michael S. Weiss and Lindsay A. Rosenwald.
Keep Reading →
November 18 - Hedge Funds, News
Bristol-Myers Squibb Co (NYSE:BMY) and Infinity Pharmaceuticals Inc.
Keep Reading →
November 10 - News, Stock Analysis
Twitter Inc (NYSE:TWTR): reported Q3 EPS of $0.13 which beat estimates by 4 cents. Revenue of $616 million was up 8.2% which beat estimates by $10.16 million.
Keep Reading →
October 27 - Earnings Report, Market Movers, News
Markets are trading on an optimistic note as all the major indices are in green zone.
Keep Reading →
October 10 - Market Movers, News
In this article we'll take a look at why VeriFone Systems Inc (NYSE:PAY), Dynavax Technologies Corporation (NASDAQ:DVAX), Gilead Sciences, Inc.
Keep Reading →
September 5 - Market Movers, News
Five Prime Therapeutics Inc (NASDAQ:FPRX) is a $1.25 billion biotech company that focuses on the discovery and development of protein therapeutics that block cancer and inflammatory...
Keep Reading →
August 31 - News, Stock Analysis
US stocks are trading slightly lower on Monday afternoon, as the major indexes retrieved from all-time highs reached on Friday, and a spike in energy stocks was not enough to ...
Keep Reading →
August 8 - Earnings Report, Market Movers, News
Bull sentiment dominated the markets during the first two trading sessions of the week, thanks to growing optimism about economic growth in the U.S after a strong jobs report, ...
Keep Reading →
July 13 - Market Movers, News
While there is no way to either deny or confirm the following statement, there is good reason to believe that hedge fund vehicles usually do not pay too much attention to insider...
Keep Reading →
June 17 - Insider Trading, News
Chicago billionaire Ken Griffin, the Founder and Chief Executive Officer of Citadel Advisors, was the highest-paid hedge fund manager in 2015, earning a stunning $1.7 billion ...
Keep Reading →
May 18 - Hedge Fund Analysis, Hedge Funds, News, Tech
It's the middle of earnings season and many investors are hungrily dissecting earnings reports and management commentary to get a better view on earnings outlooks for the future...
Keep Reading →
April 28 - Market Movers, News
Last week was marked by the S&P 500 entering into its eighth year of bull run amid an increase in oil prices and hopes of more stimulus from central banks.
Keep Reading →
March 15 - News
Hedge fund managers like David Einhorn, Dan Loeb, and Carl Icahn became billionaires by reaping large profits for their investors, which is why piggybacking their stock picks ...
Keep Reading →
March 9 - Hedge Fund Analysis, Hedge Funds, News
Large-cap stocks are generally less immune to sharp moves based on rumors than their mid and small-cap counterparts.
Keep Reading →
December 14 - Hedge Funds, News
You probably know from experience that there is not as much information on small-cap companies as there is on large companies.
Keep Reading →
December 1 - Hedge Funds, News
Clifford Fox's Columbus Circle Investors is a multi-billion dollar investment management firm that has been primarily successful in picking small-cap and mid-cap stocks over ...
Keep Reading →
November 6 - Hedge Fund Analysis, Hedge Funds, News
It's Thursday and shareholders of BofI Holding, Inc.
Keep Reading →
October 15 - Market Movers, News
Zweig-DiMenna Partners is a US-based hedge fund managed by Joseph A. DiMenna, who co-founded the fund with Martin Zweig back in 1984.
Keep Reading →
May 19 - Hedge Funds, News
According to a Schedule 13D form filed yesterday with the Securities and Exchange Commission, Samuel Islay's Orbimed Advisors has slashed its stake in Intercept Pharmaceuticals...
Keep Reading →
March 26 - Hedge Funds, News
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc.
Keep Reading →
September 9 - News
Orbimed Advisors, led by Samuel Isaly, recently published its 13F filing with the U.S. Securities and Exchange Commission.
Keep Reading →
August 28 - Hedge Funds, News
Ghost Tree Capital is a healthcare-oriented hedge fund headquartered in New York.
Keep Reading →
February 27 - Hedge Funds, News
Stan Druckenmiller is a billionaire, and was the long-time manager of Duquesne Capital. Now, he oversees a family office, but his investing strategy is mostly the same.
Keep Reading →
February 24 - Hedge Funds, News
In a latest 13F filing, Stanley Druckenmiller’s fund Duquesne Capital, revealed its holdings for the fourth quarter of 2013.
Keep Reading →
February 20 - Hedge Funds, News
Innovation is everything when it comes to the pharmaceutical sector.
Keep Reading →
September 23 - News
Through the years, London-based drugmaker AstraZeneca plc (ADR) (NYSE:AZN) and U.S. pharmaceutical firm Merck & Co., Inc.
Keep Reading →
September 17 - News
AstraZeneca plc (ADR) (NYSE:AZN) may have missed out on acquiring the oncology platform of Onyx Pharmaceuticals, but it responded by pulling the trigger on a $500 million deal...
Keep Reading →
September 15 - News
A couple months may not seem like a long time, but when you're diagnosed with pancreatic cancer, the prospect of a few months makes a huge difference.
Keep Reading →
September 13 - Dividend Stocks, News
As the CEO of ConocoPhillips (NYSE:COP), the largest independent oil company in the nation, Ryan Lance was happy to address the pros and cons of hydraulic fracturing - or "fracking...
Keep Reading →
September 12 - Dividend Stocks, News
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Keep Reading →
September 6 - News
The big biotech announced on Thursday that updated results from its phase 3 study of Pomalyst in treating relapsed or refractory multiple myeloma had been published online in ...
Keep Reading →
September 5 - News
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX) is being scooped up by Tokyo-based Otsuka Pharmaceuticals.
Keep Reading →
September 5 - News
